Maqola mavzusi

Mualliflar

Shomurodova Muxayo Rahmonovna

Muassasa

Buxoro davlat tibbiyot instituti

Annotatsiya

Immunoterapiya saraton kasalligini davolashning innovatsion usuli hisoblanadi. Bu bemorning immun tizimining o'zaro ta'siriga va yomon sifatli o'simtaga aylanishiga asoslangan. Immunoterapiya davolashning klassik usullari bilan qo’llaniladi [Ivanisova D.N., 2022]. Kimyoterapiya paytida o'pka saratoni bilan og'rigan saraton kasalliklarini kompleks davolashda immunomodulyatorlardan foydalanish bo'yicha adabiyotlarni tahlil qilish natijalari keltirilgan.

Kalit so'zlar

morfometriya, saraton, o'pka, immunomodulyator, kimyoterapiya.

Adabiyotlar

1. Costa DB, Shaw AT, Ou S-HI, Solomon BJ, Riely GJ, Ahn M-J, et al. Clinical Experience with Crizotinib in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015 Jun 10;33(17):1881–1888.
2. Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963–1971. https://doi.org/10.1056/nejmoa1406766
3. Giroux Leprieur E, Dumenil C, Julie C, Giraud V, Dumoulin J, Labrune S, et al. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. Eur J Cancer. 2017;78:16–23. https://doi.org/10.1016/j.ejca.2016.12.041
4. Кузьминов А. Е., Лактионов К. К., Егорова А. В., Бредер В. В., Барболина Т. Д. Иммунотерапия мелкоклеточного рака легкого // МС. 2019. №10. URL: https://cyberleninka.ru/article/n/immunoterapiyamelkokletochnogo-raka-legkogo (дата обращения: 03.05.2023).
5. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013 Jun;137(6):828–860. https://doi.org/10.5858/arpa.2012-0720-OA
6. De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, RaHagen Fritz Kennecke, Carl J Brown, Jonathan M. Loree, et al. CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial. Journal of Clinical Oncology. 2021 May 20; 39 (no.15_suppl): 3508-3508.
7. Young M.R. Th17 Cells in Protection from Tumor or Promotion of Tumor Progression. J Clin Cell Immunol. 2016;7(3):431.
8. Ishii H., Azuma K., Kawahara A., Yamada K., Imamura Y., Tokito T., et al. Signifcance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10(3):426–30.